An estimation of BRAF V600E status in the initial course of the disease could not only help to avoid overtreatment in a patient with a less aggressive cancer phenotype (BRAF negative PTCs) but also to predict the treatment response in those with a BRAF positive status. This evidence concerns the gene BRAF and cancer.